Abstract 4083: Diabetic Patients Requiring Insulin Therapy Have Worse Clinical Outcome after Drug-Eluting Stent Implantation: Multicenter Registry in Asia
Background and Aim: Drug-eluting stents prevent restenosis across wide range patients. However, no studies comparing the effect of drug-eluting stents in patients with insulin required diabetes mellitus (IDDM) and non-insulin required DM (NIDDM) is yet available. The aim of this study is to compare the difference of clinical efficacy of drug-eluting stent in patients with IDDM and NIDDM.
Methods: A prospective analysis of 1510 consecutive patients with DM (IDDM 426, NIDDM 1084) in five high volume Asian centers after successful stenting was performed. Patients were treated with bare metal stents (BMS) (IDDM 180, NIDDM 474), Sirolimus-eluting stent (SES) (IDDM 128, NIDDM 340) and Paclitaxel-eluting stents (PES) (IDDM 118, NIDDM 270). The study endpoints were major adverse cardiac events (MACE) at 30 days, 9 months and restenosis rate and target lesion revascularization (TLR) in each group.
Results: The baseline clinical characteristics between 4 groups were similar. See table⇓ for clinical results.
The use of drug-eluting stents in patients with DM was safe and feasible.
Diabetic patients required insulin therapy have higher risk of restenosis, TLR and MACE including death or myocardial infarction.